BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201027
DTEND;VALUE=DATE:20201030
DTSTAMP:20260515T123020
CREATED:20200722T112338Z
LAST-MODIFIED:20200722T112338Z
UID:26438-1603756800-1604015999@www.pharmajournalist.com
SUMMARY:Macrophage-directed Therapies Summit 2020
DESCRIPTION:Harnessing the Potential of Macrophage Therapies Using Small Molecule\, Antibody & Cell Therapy based Approaches for Oncology and Beyond \nWith the explosive excitement and clinical proof of concepts utilizing CD47 approaches\, macrophage-directed therapies have started to witness interest and investment in novel macrophage targets outside of CD47. \n \nThe 2nd Macrophage-directed Therapies Summit is focused on optimizing the potential of macrophage therapies\, through direct utilization of cells or small molecule approaches to target and stimulate macrophage cells in vivo for oncological indications and beyond. \nBringing together the leading experts\, we will explore the clinical development of CD47 checkpoint blockades\, combination strategies\, macrophage repolarization approaches and engineered macrophages. \nJoin the trailblazers of macrophage therapeutic development\, from the likes of Carisma Therapeutics\, Faron Pharmaceuticals\, and Verseau Therapeutic\, as we come together to advance the fundamental understanding of macrophage biology\, avoiding on-target toxicities and the emerging field of macrophage cellular immunotherapy.
URL:https://www.pharmajournalist.com/event/macrophage-directed-therapies-summit-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201028
DTEND;VALUE=DATE:20201030
DTSTAMP:20260515T123020
CREATED:20171009T143124Z
LAST-MODIFIED:20200810T095904Z
UID:3348-1603843200-1604015999@www.pharmajournalist.com
SUMMARY:Pharmaceutical Microbiology East Coast
DESCRIPTION:SMi’s 3rd Annual Pharmaceutical Microbiology East Coast\nConference: 28 – 29 October 2020\nLocation: Virtual Event\nWebsite: www.microbiologyeastcoast.com/PJWL \nSPONSORED BY: Associates of Cape Cod\, bioMérieux\, Bioscience International\, C.T.L. MAT\, LONZA \nCHAIRED BY: Lynne Ensor\,VP Technical\, Parexel \nExploring the current approaches towards improved contamination control \nThe pharmaceutical microbiology industry has seen many changes during the progression into the 21st century. With advances in rapid microbiological methods\, revisions being made to regulations in the industry\, enhanced knowledge of the human microbiome\, and novel testing methods\, this industry is ever expanding. \nJoin industry experts to discuss and analyze the latest advances and challenges within the industry. Network with industry professionals\, discuss the revision of Annex 1\, explore data integrity considerations for conventional and rapid microbiology methods\, analyze arising issues with environmental monitoring and gain insight into an industry perspective on automated endotoxin testing and process automation. \nEvent Hashtag: #SMiPharmaMicroEC \nHIGHLIGHTS FOR 2020: \n\nDiscuss ongoing complication of personnel derived contaminations from the FDA\nGain valuable insight towards microbiological quality considerations in non-sterile manufacturing and control of BCC from Parexel\nLearn from the perspective of the US Pharmacopeia on container closure integrity evaluation\nExamine an end-to-end contamination risk assessment for autologous cell therapy from Juno Therapeutics\nExplore a back to back Genentech session covering technical considerations for microbial QC of raw materials used in biotechnology and the past\, current and future state of Mycoplasma testing\n\nThe Use of Recombinant Chromogenic Assays as Alternate Methods for the Bacterial Endotoxins Test (BET) \nWorkshop Leader:\nVeronika Wills\, Manager\, Technical Services\, Associates of Cape Cod \nView the full agenda: www.microbiologyeastcoast.com/PJWL \nWHO SHOULD ATTEND \nSenior Microbiologist\, Lead Scientist\, Laboratory Manager\, QA Specialist\, Drug Substance External Manufacturer\, QC Scientists\, Heads of Quality\, Business Development Manager\, Pharmaceutical Microbiology Consultant\, Higher Pharmacopoeia Scientist\, Analytical Standards Specialist \nTo know more about Pharmaceutical Microbiology East Coast please click here.
URL:https://www.pharmajournalist.com/event/pharmaceutical-microbiology-east-coast/
LOCATION:Virtual Event
ORGANIZER;CN="SMi Group Ltd":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201028
DTEND;VALUE=DATE:20201030
DTSTAMP:20260515T123020
CREATED:20200812T084028Z
LAST-MODIFIED:20200812T084028Z
UID:26683-1603843200-1604015999@www.pharmajournalist.com
SUMMARY:Dry AMD Therapeutic Development Summit
DESCRIPTION:Finding new therapeutics to counter the progression of Dry AMD and prevent the geographical atrophy has never been more important. The aging population creates an ever-growing clinical need for next-generation therapeutics. \nThis action-packed two-day digital agenda holds 22 Presentations from industry and academic leaders\, a virtual poster session and 5+ hours of networking\, you can join the only platform discussing issues present in the development of Dry AMD therapeutics. \n \nJoin this critical global forum which will be uniting industry specialists from pharma\, biotechs\, academia and solution providers as we target the most pressing issues important to bringing the next generation of Dry AMD drugs to market. \nCompanies speaking include: Genentech\, 4D Molecular Therapeutics\, Alkeus Pharmaceuticals\, Inc.\, Boehringer Ingelheim International GmbH\, University of California\, San Francisco\, Regenerative Patch Technologies\, Novartis\, Stealth BioTherapeutics Inc \nFind out more here > https://ter.li/mc1pmz
URL:https://www.pharmajournalist.com/event/dry-amd-therapeutic-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201029
DTEND;VALUE=DATE:20201031
DTSTAMP:20260515T123020
CREATED:20200709T091800Z
LAST-MODIFIED:20200709T092312Z
UID:26239-1603929600-1604102399@www.pharmajournalist.com
SUMMARY:Patient-to-Patient Supply for Cell Immunotherapies Summit
DESCRIPTION:Achieving Standardization & Operational Excellence in Vein-to-Vein Supply \nAs an increasing number of candidates enter the clinic and promise to be a mainstay in the future of cancer treatment\, cell therapies pose unique supply chain challenges. \n \nAt the inaugural Patient-to-Patient Supply for Cell Immunotherapies Summit\, this community will share their expertise and propose best practice for seamless vein-to-vein delivery at the clinical and commercial scale. \nFrom time and temperature sensitivity\, to patient-facing service and integrated platforms\, a seamless vein-to-vein supply chain is central in maintaining cell immunotherapy safety and efficacy at scale and maximizing the patient experience. \nJoin the strategic experts from GSK\, bluebird bio\, Adaptimmune\, Celgene\, BMS and more\, to discuss best practice for patient-facing supply chains and build integrated platforms for chain of identity and end-user access.
URL:https://www.pharmajournalist.com/event/patient-to-patient-supply-for-cell-immunotherapies-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR